Evotec and X-Chem Collaborate to Boost Early-Stage Drug Discovery

Evotec SE has formed a collaboration with X-Chem to advance early-stage drug discovery. X-Chem’s DNA-encoded library (DEL) technology enables the simultaneous screening of billions of DNA-tagged compounds, significantly enhancing the identification of promising starting points for drug development.

By combining Evotec’s extensive screening capabilities with X-Chem’s DEL technology, including DELflex—a traditional DEL screening approach—and HITMiner, a machine learning platform that uses high-quality experimental DEL data, the partnership aims to deliver optimal drug intervention solutions for challenging biological targets.

Karen Lackey, CEO of X-Chem, emphasized the importance of partnerships in advancing drug discovery, stating, “Access to best-in-class platforms is critical for addressing the complexities in this field.” Craig Johnstone, COO of Evotec, echoed this sentiment, highlighting the benefits of X-Chem’s DEL platform and its potential to tackle innovative and complex biological targets.